A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice

Dayoung Oh, Evelyn Walenta, Taro E. Akiyama, William S. Lagakos, Denise Lackey, Ariane R. Pessentheiner, Roman Sasik, Nasun Hah, Tyler J. Chi, Jason M. Cox, Mary Ann Powels, Jerry Di Salvo, Christopher Sinz, Steven M. Watkins, Aaron M. Armando, Heekyung Chung, Ronald M. Evans, Oswald Quehenberger, Joanne McNelis, Juliane G. Bogner-Strauss & 1 others Jerrold M. Olefsky

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed to them, including reduced plasma triglyceride levels, amelioration of atherosclerosis and increased insulin sensitivity. We reported that Gpr120 is the functional receptor for these fatty acids and that ω-3-FAs produce robust anti-inflammatory, insulin-sensitizing effects, both in vivo and in vitro, in a Gpr120-dependent manner. Indeed, genetic variants that predispose to obesity and diabetes have been described in the gene encoding GPR120 in humans (FFAR4). However, the amount of fish oils that would have to be consumed to sustain chronic agonism of Gpr120 is too high to be practical, and, thus, a high-affinity small-molecule Gpr120 agonist would be of potential clinical benefit. Accordingly, Gpr120 is a widely studied drug discovery target within the pharmaceutical industry. Gpr40 is another lipid-sensing G protein-coupled receptor, and it has been difficult to identify compounds with a high degree of selectivity for Gpr120 over Gpr40 (ref. 11). Here we report that a selective high-affinity, orally available, small-molecule Gpr120 agonist (cpdA) exerts potent anti-inflammatory effects on macrophages in vitro and in obese mice in vivo. Gpr120 agonist treatment of high-fat diet-fed obese mice causes improved glucose tolerance, decreased hyperinsulinemia, increased insulin sensitivity and decreased hepatic steatosis. This suggests that Gpr120 agonists could become new insulin-sensitizing drugs for the treatment of type 2 diabetes and other human insulin-resistant states in the future.

Original languageEnglish (US)
Pages (from-to)942-947
Number of pages6
JournalNature Medicine
Volume20
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Obese Mice
Insulin Resistance
Anti-Inflammatory Agents
Insulin
Inflammation
Fatty Acids
Fish Products
Medical problems
Fish Oils
Omega-3 Fatty Acids
Drug Industry
Hyperinsulinism
High Fat Diet
Insurance Benefits
Drug Discovery
G-Protein-Coupled Receptors
Dietary Supplements
Fish products
Pharmaceutical Preparations
Dietary supplements

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Oh, D., Walenta, E., Akiyama, T. E., Lagakos, W. S., Lackey, D., Pessentheiner, A. R., ... Olefsky, J. M. (2014). A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nature Medicine, 20(8), 942-947. https://doi.org/10.1038/nm.3614

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. / Oh, Dayoung; Walenta, Evelyn; Akiyama, Taro E.; Lagakos, William S.; Lackey, Denise; Pessentheiner, Ariane R.; Sasik, Roman; Hah, Nasun; Chi, Tyler J.; Cox, Jason M.; Powels, Mary Ann; Di Salvo, Jerry; Sinz, Christopher; Watkins, Steven M.; Armando, Aaron M.; Chung, Heekyung; Evans, Ronald M.; Quehenberger, Oswald; McNelis, Joanne; Bogner-Strauss, Juliane G.; Olefsky, Jerrold M.

In: Nature Medicine, Vol. 20, No. 8, 01.01.2014, p. 942-947.

Research output: Contribution to journalArticle

Oh, D, Walenta, E, Akiyama, TE, Lagakos, WS, Lackey, D, Pessentheiner, AR, Sasik, R, Hah, N, Chi, TJ, Cox, JM, Powels, MA, Di Salvo, J, Sinz, C, Watkins, SM, Armando, AM, Chung, H, Evans, RM, Quehenberger, O, McNelis, J, Bogner-Strauss, JG & Olefsky, JM 2014, 'A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice', Nature Medicine, vol. 20, no. 8, pp. 942-947. https://doi.org/10.1038/nm.3614
Oh D, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nature Medicine. 2014 Jan 1;20(8):942-947. https://doi.org/10.1038/nm.3614
Oh, Dayoung ; Walenta, Evelyn ; Akiyama, Taro E. ; Lagakos, William S. ; Lackey, Denise ; Pessentheiner, Ariane R. ; Sasik, Roman ; Hah, Nasun ; Chi, Tyler J. ; Cox, Jason M. ; Powels, Mary Ann ; Di Salvo, Jerry ; Sinz, Christopher ; Watkins, Steven M. ; Armando, Aaron M. ; Chung, Heekyung ; Evans, Ronald M. ; Quehenberger, Oswald ; McNelis, Joanne ; Bogner-Strauss, Juliane G. ; Olefsky, Jerrold M. / A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. In: Nature Medicine. 2014 ; Vol. 20, No. 8. pp. 942-947.
@article{9d98c041624c412880d0a5bf90dcb888,
title = "A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice",
abstract = "It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed to them, including reduced plasma triglyceride levels, amelioration of atherosclerosis and increased insulin sensitivity. We reported that Gpr120 is the functional receptor for these fatty acids and that ω-3-FAs produce robust anti-inflammatory, insulin-sensitizing effects, both in vivo and in vitro, in a Gpr120-dependent manner. Indeed, genetic variants that predispose to obesity and diabetes have been described in the gene encoding GPR120 in humans (FFAR4). However, the amount of fish oils that would have to be consumed to sustain chronic agonism of Gpr120 is too high to be practical, and, thus, a high-affinity small-molecule Gpr120 agonist would be of potential clinical benefit. Accordingly, Gpr120 is a widely studied drug discovery target within the pharmaceutical industry. Gpr40 is another lipid-sensing G protein-coupled receptor, and it has been difficult to identify compounds with a high degree of selectivity for Gpr120 over Gpr40 (ref. 11). Here we report that a selective high-affinity, orally available, small-molecule Gpr120 agonist (cpdA) exerts potent anti-inflammatory effects on macrophages in vitro and in obese mice in vivo. Gpr120 agonist treatment of high-fat diet-fed obese mice causes improved glucose tolerance, decreased hyperinsulinemia, increased insulin sensitivity and decreased hepatic steatosis. This suggests that Gpr120 agonists could become new insulin-sensitizing drugs for the treatment of type 2 diabetes and other human insulin-resistant states in the future.",
author = "Dayoung Oh and Evelyn Walenta and Akiyama, {Taro E.} and Lagakos, {William S.} and Denise Lackey and Pessentheiner, {Ariane R.} and Roman Sasik and Nasun Hah and Chi, {Tyler J.} and Cox, {Jason M.} and Powels, {Mary Ann} and {Di Salvo}, Jerry and Christopher Sinz and Watkins, {Steven M.} and Armando, {Aaron M.} and Heekyung Chung and Evans, {Ronald M.} and Oswald Quehenberger and Joanne McNelis and Bogner-Strauss, {Juliane G.} and Olefsky, {Jerrold M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/nm.3614",
language = "English (US)",
volume = "20",
pages = "942--947",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice

AU - Oh, Dayoung

AU - Walenta, Evelyn

AU - Akiyama, Taro E.

AU - Lagakos, William S.

AU - Lackey, Denise

AU - Pessentheiner, Ariane R.

AU - Sasik, Roman

AU - Hah, Nasun

AU - Chi, Tyler J.

AU - Cox, Jason M.

AU - Powels, Mary Ann

AU - Di Salvo, Jerry

AU - Sinz, Christopher

AU - Watkins, Steven M.

AU - Armando, Aaron M.

AU - Chung, Heekyung

AU - Evans, Ronald M.

AU - Quehenberger, Oswald

AU - McNelis, Joanne

AU - Bogner-Strauss, Juliane G.

AU - Olefsky, Jerrold M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed to them, including reduced plasma triglyceride levels, amelioration of atherosclerosis and increased insulin sensitivity. We reported that Gpr120 is the functional receptor for these fatty acids and that ω-3-FAs produce robust anti-inflammatory, insulin-sensitizing effects, both in vivo and in vitro, in a Gpr120-dependent manner. Indeed, genetic variants that predispose to obesity and diabetes have been described in the gene encoding GPR120 in humans (FFAR4). However, the amount of fish oils that would have to be consumed to sustain chronic agonism of Gpr120 is too high to be practical, and, thus, a high-affinity small-molecule Gpr120 agonist would be of potential clinical benefit. Accordingly, Gpr120 is a widely studied drug discovery target within the pharmaceutical industry. Gpr40 is another lipid-sensing G protein-coupled receptor, and it has been difficult to identify compounds with a high degree of selectivity for Gpr120 over Gpr40 (ref. 11). Here we report that a selective high-affinity, orally available, small-molecule Gpr120 agonist (cpdA) exerts potent anti-inflammatory effects on macrophages in vitro and in obese mice in vivo. Gpr120 agonist treatment of high-fat diet-fed obese mice causes improved glucose tolerance, decreased hyperinsulinemia, increased insulin sensitivity and decreased hepatic steatosis. This suggests that Gpr120 agonists could become new insulin-sensitizing drugs for the treatment of type 2 diabetes and other human insulin-resistant states in the future.

AB - It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed to them, including reduced plasma triglyceride levels, amelioration of atherosclerosis and increased insulin sensitivity. We reported that Gpr120 is the functional receptor for these fatty acids and that ω-3-FAs produce robust anti-inflammatory, insulin-sensitizing effects, both in vivo and in vitro, in a Gpr120-dependent manner. Indeed, genetic variants that predispose to obesity and diabetes have been described in the gene encoding GPR120 in humans (FFAR4). However, the amount of fish oils that would have to be consumed to sustain chronic agonism of Gpr120 is too high to be practical, and, thus, a high-affinity small-molecule Gpr120 agonist would be of potential clinical benefit. Accordingly, Gpr120 is a widely studied drug discovery target within the pharmaceutical industry. Gpr40 is another lipid-sensing G protein-coupled receptor, and it has been difficult to identify compounds with a high degree of selectivity for Gpr120 over Gpr40 (ref. 11). Here we report that a selective high-affinity, orally available, small-molecule Gpr120 agonist (cpdA) exerts potent anti-inflammatory effects on macrophages in vitro and in obese mice in vivo. Gpr120 agonist treatment of high-fat diet-fed obese mice causes improved glucose tolerance, decreased hyperinsulinemia, increased insulin sensitivity and decreased hepatic steatosis. This suggests that Gpr120 agonists could become new insulin-sensitizing drugs for the treatment of type 2 diabetes and other human insulin-resistant states in the future.

UR - http://www.scopus.com/inward/record.url?scp=84907612482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907612482&partnerID=8YFLogxK

U2 - 10.1038/nm.3614

DO - 10.1038/nm.3614

M3 - Article

VL - 20

SP - 942

EP - 947

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 8

ER -